Extending anti-clotting treatment after distal deep vein thrombosis could reduce further clot risk

AI background business technology, digital transformation

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after treatment, finds a trial published by The BMJ today.

Wordle today: Here’s the answer, hints for November 24

Previous article

VTC scientist wins $2.7 million to investigate viral infection of the heart that can cause sudden death

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations